Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
2010 · Journal of Clinical Oncology · 591 citations
https://doi.org/10.1200/jco.2009.26.2071
S
Scott N. Holden
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
48
Papers
4.7K
Citations
25
h-index
31
i10-index
Scott N. Holden is an academic researcher. The author has contributed to research in topics: Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research & Colorectal Cancer Treatments and Studies. The author has an h-index of 25, co-authored 41 publications.
Papers by this author
worksClinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
2012 · Cancer Chemotherapy and Pharmacology · 262 citations
https://doi.org/10.1007/s00280-011-1817-3
Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
2011 · Clinical Breast Cancer · 105 citations
https://doi.org/10.1016/j.clbc.2011.03.018
A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer
2012 · Cancer · 102 citations
https://doi.org/10.1002/cncr.27622
Impact of Food and the Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of GDC-0941 in Healthy Volunteers: Bench to Bedside Investigation of pH-Dependent Solubility
2013 · Molecular Pharmaceutics · 17 citations
https://doi.org/10.1021/mp4005595
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat